Physician profile
Gary H Levin
NPI 1568440592
$876.97
in general payments reported to CMS, 2019-2025
20 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $51.57 · 2021: $36.42 · 2022: $145 · 2023: $113 · 2024: $162 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.60 | 2019-2025 | |
| Celgene Corporation | $107.05 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $67.40 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $52.85 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $49.56 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.70 | 2019-2023 | Trulance |
| Allergan, INC. | $38.02 | 2019 | |
| Madrigal Pharmaceuticals | $31.14 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $30.89 | 2019-2025 | |
| Braintree Laboratories, INC. | $22.15 | 2019-2020 | |
| Fujifilm Healthcare Americas Corporation | $22.04 | 2021 | |
| Qol Medical, LLC | $21.28 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $18.90 | 2024 | Dupixent |
| Pfizer INC. | $16.98 | 2024 | |
| Aimmune Therapeutics, INC. | $15.63 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $13.95 | 2019 | |
| Shire North American Group INC | $13.66 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.80 | 2022 | |
| Merck Sharp & Dohme LLC | $12.37 | 2020 | |
| Erbe USA INC | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.